This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Congenital hyperinsulinism (CHI) and the potential of Rezolute's RZ358
Ticker(s): RZLTWho's the expert?
Institution: Cook Children's Medical Center
- Director of Cook Children's Endocrinology department and former Clinical director of the Congenital Hyperinsulinism Center at the Children's Hospital of Philadelphia.
- Leads one of the first programs in the nation, Cook Children's Hyperinsulinism Center, applying a specialized team approach to treat hyperinsulinism
- Runs a hyperinsulinism clinic with ~130 patients with genetic forms of hyperinsulinism, 70-80 patients with transient forms of hyperinsulinism, and patients with syndrome and insulinoma.
- Knowledgeable about CRN04777, RZ358, and Avextide and is involved in developing studies for 2 of those 3 drugs.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
